Anticancer

Anemosapogenin
Catalog No: CFN90310

Anemosapogenin shows potent anti-tumor effect in vivo, but it has some toxicity, structure modification should be needed.

Artesunate
Catalog No: CFN90313

Artesunate is a part of the artemisinin group of agents with an IC50 of < 5 μM for small cell lung carcinoma cell line H69. It is a potential inhibitor of STAT-3 and exhibits selective cytotoxicity of cancer cells over normal cells in vitro; A potent inhibitor of EXP1.Artesunate has anti-inflammatory activity, can prevent neuroinflammation in BV2 microglia by interfering with NF-κB and p38 MAPK signalling.

Capillarisin
Catalog No: CFN90317

Capillarisin is a novel blocker of STAT3 activation and thus may have a potential in negative regulation of growth, metastasis, and chemoresistance of tumor cells, it inhibits cancer cell growth of osteosarcoma cells by inducing apoptosis accompanied with G0/G1-phase cell cycle arrest and loss in mitochondrial membrane potential.Capillarisin has anti-inflammatory activity, can inhibit LPS-induced inflammation by blocking TLR4-mediated NF-κB and MAPKs activation in BV2 microglia. Capillarisin possesses promising anti-hyperalgesic and anti-allodynic effects through the inhibition of various inflammatory pain signaling.

Catharanthine Tartrate
Catalog No: CFN90318

Catharanthine Tartrate is an anti-tumor drug. Catharanthine Tartrate binds with DNA in a mode of groove binding, Se(Ⅳ)can inhibit the binding of Catharanthine Tartrate and DNA.

Paclitaxel
Catalog No: CFN97759

Paclitaxel is a potent anticancer medication which can promote microtubule (MT) assembly, inhibits MT depolymerization, and changes MT dynamics required for mitosis and cell proliferation. Paclitaxel can induce ototoxicity in rats.